Retinitis Pigmentosa (RP) is a wide array of progressive debilitating visual disorders caused by one of many possible genetic mutations, which leads to photoreceptor degeneration and ultimately loss of vision. While AAV-mediated gene replacement therapies have recently ameliorated a small subset of patients with a specific genetic mutation, a comprehensive, mutation-independent treatment is currently unavailable. Most genes mutated in RP are expressed solely in rods, and the mutations lead to rod degeneration and night blindness. Unfortunately, rod death is followed by secondary cone degeneration, which is ultimately responsible for decreased quality of life. Our lab’s goal is to develop novel gene therapies to prolong cone survival that can be used for all patients with RP.